MedWatch

Orphazyme CEO stays silent in run-up to creditor meeting

Anders Vadsholt, CFO and acting CEO of Orphazyme, doesn’t want to speak about any recent or past events that led to the ongoing in-court restructuring process while it takes place, he informs MedWatch in a text message.

Anders Vadsholt, CFO and acting CEO of Orphazyme | Photo: Orphazyme / PR

A line of defeats has been trailing biotech firm Orphazyme the past year, and the company recently announced that it is undergoing an in-court restructuring process.

Anders Vadsholt, Orphazyme’s chief financial officer of six years and acting chief executive as of March, has no comment, he informs MedWatch in a text message.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs